Lexicon reports Q1 EPS (17c), consensus (18c)

Reports as of March 31 Lexicon had $105.9M in cash and investments, as compared to $138.4M as of December 31. "Our NDA for sotagliflozin for the treatment of heart failure is on track for its May 27th PDUFA action date," said Lonnel Coats, Lexicon’s chief executive officer. "With both recently adopted medical treatment guidelines recommending the use of SGLT inhibitors as a key pillar of heart failure treatment and the unique data from our SOLOIST-WHF trial, we believe we have a strong value proposition for clinical differentiation in the heart failure market. Should we receive regulatory approval, we are prepared to promptly launch in the United States in the first half of 2023." "As we have previously shared, we continue preparations to advance LX9211 into late-stage development in neuropathic pain, supported by data from Phase 2 proof-of-concept studies in diabetic peripheral neuropathic pain and postherpetic neuralgia both completed in 2022, and expect feedback from our interactions from the FDA in Q2."As of March 31 Lexicon had $105.9M in cash and investments, as compared to $138.4 million as of December 31.